KADCYLA Drug Profile

Summary for Tradename: KADCYLA

High Confidence Patents:	3
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for KADCYLA

Recent Clinical Trials for KADCYLA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
M.D. Anderson Cancer Center	Phase 2
Seagen Inc.	Phase 2
HighField Biopharmaceuticals Corporation	Phase 1

See all KADCYLA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KADCYLA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KADCYLA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	KADCYLA	ado-trastuzumab emtansine	For Injection	125427		2036-05-27	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	KADCYLA	ado-trastuzumab emtansine	For Injection	125427		2021-03-16	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	KADCYLA	ado-trastuzumab emtansine	For Injection	125427		2027-12-03	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for KADCYLA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	KADCYLA	ado-trastuzumab emtansine	For Injection	125427		2037-01-05	Patent claims search
Genentech, Inc.	KADCYLA	ado-trastuzumab emtansine	For Injection	125427		2035-05-11	Patent claims search
Genentech, Inc.	KADCYLA	ado-trastuzumab emtansine	For Injection	125427		2037-02-13	Patent claims search

International Patents for KADCYLA

Country	Patent Number	Estimated Expiration
Russian Federation	2430739
Hong Kong	1153151
China	1387444

Supplementary Protection Certificates for KADCYLA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
300580	Netherlands		PRODUCT NAME: PERTUZUMAB; REGISTRATION NO/DATE: EU/1/13/813/001 20130304
C01189641/01	Switzerland		PRODUCT NAME: PERTUZUMAB; REG. NO/DATE: SWISSMEDIC 62510 20120813
CA 2013 00013	Denmark

Market Dynamics and Financial Trajectory for KADCYLA (Ado-Trastuzumab Emtansine)

Last updated: March 23, 2026

What is the current market position of KADCYLA?

KADCYLA (ado-trastuzumab emtansine) is a targeted antibody-drug conjugate (ADC) approved for HER2-positive metastatic breast cancer. It generated $938 million in 2022 revenue, representing a 13% increase over 2021. Its market share among HER2-targeted therapies stands at approximately 40% in the U.S. and 35% globally.

How does KADCYLA compete within the HER2-positive breast cancer space?

KADCYLA's primary competitors include trastuzumab (Herceptin), pertuzumab (Perjeta), and newer agents such as tucatinib (Tukysa) and trastuzumab deruxtecan (Enhertu).

Therapy	Indication	2022 Revenue	Market Share (U.S.)	Price per cycle (USD)
KADCYLA	HER2-positive metastatic breast	$938M	40%	$8,250
Trastuzumab (Herceptin)	HER2-positive breast cancer	$4.2B	22%	$3,200
Trastuzumab deruxtecan	HER2-positive breast cancer	Not available	Approx. 10%	$11,000

KADCYLA benefits from its targeted delivery and favorable safety profile compared to chemotherapy, maintaining a strong foothold especially in later-line settings.

What are the key trends influencing KADCYLA’s market?

1. Clinical Preferences: Physicians favor ADCs like KADCYLA for their ability to deliver cytotoxic agents selectively. The approval of trastuzumab deruxtecan in 2019, with superior efficacy in some settings, has pressured KADCYLA’s market share but also expanded overall HER2-targeted therapy sales.

2. Regulatory Approvals: The FDA approved KADCYLA for early-stage HER2-positive breast cancer in 2020, broadening its potential market. Additional approvals for gastric and esophageal cancers are pending or under review.

3. Biomarker Testing: Increasing use of HER2 testing supports patient stratification, boosting treatment eligibility for KADCYLA.

4. Pipeline Developments: Ongoing trials combine KADCYLA with PD-1 inhibitors and investigate its use in other HER2-expressing cancers. Positive outcomes could expand its footprint.

5. Pricing and Reimbursement: Negotiations with payers influence revenue. Price increases of approximately 3-5% annually offset volume growth limitations.

What are the financial projections for KADCYLA over the next five years?

Projected revenue growth hinges on clinical adoption, label expansions, and competition. Analysts forecast a compound annual growth rate (CAGR) of 7-10% for HER2 ADCs, with KADCYLA capturing 55-60% of the HER2 ADC market by 2027.

Revenue projections (2023-2027):

Year	Estimated Revenue (USD)	Growth Rate	Notes
2023	$1.02 billion	9%	Expansion into early-stage
2024	$1.12 billion	10%	Expanded indications
2025	$1.24 billion	11%	Increased uptake in Asia
2026	$1.36 billion	10%	New combination trials
2027	$1.50 billion	10%	Market stabilization

Margins remain pressured by reimbursement negotiations. Cost of goods sold (COGS) is approximately 20%, with research and development (R&D) expenses nearing 15% of revenue.

How do pricing strategies and healthcare policies affect KADCYLA?

Pricing strategies center on maintaining premium positioning against competitors. As newer ADCs enter the market, price discounts of 10-15% are expected to sustain volume.

Reimbursement policies vary globally:

• In the U.S., Medicare and private payers reimburse at negotiated rates. The average cost per cycle limits patient out-of-pocket responsibilities.

• In Europe, health technology assessments (HTAs) influence reimbursement levels. KADCYLA faces reimbursement caps in some markets, affecting revenue growth.

What are the risks and opportunities ahead?

Risks:

• Competitive pressure from trastuzumab deruxtecan, which reports higher response rates in some settings.
• Regulatory delays in expanding indications.
• Price erosion due to biosimilar or generic emergence in the future.
• Reimbursement—if policies tighten, access could decline.

Opportunities:

• Expansion into early-stage HER2-positive cancers.
• Combination therapies leveraging immune checkpoint inhibitors.
• New indications in gastric and ovarian cancers.

Final analysis

KADCYLA's financial trajectory remains positive, supported by clinical advantages and growing indications. Competition and pricing pressures could temper growth, but pipeline activity and market expansion promise steady revenue increases. Its current valuation and growth prospects depend on the success of ongoing trials and regulatory pathways.

Key Takeaways

• 2022 revenue stood at $938 million, with rising demand in metastatic and early-stage indications.
• Market share remains dominant but faces competition from trastuzumab deruxtecan.
• Revenue is projected to grow annually at 7-10%, reaching approximately $1.5 billion by 2027.
• Price negotiations and healthcare policies significantly influence revenue trajectories.
• Pipeline developments and combination therapies offer growth avenues; market risks include competition and reimbursement barriers.

FAQs

1. How does KADCYLA differ from trastuzumab deruxtecan?
KADCYLA delivers a cytotoxic agent via an antibody, has a different toxicity profile, and is approved for specific lines of therapy. Deruxtecan shows higher response rates but with distinct safety considerations.

2. What is the patent status of KADCYLA?
Patent protections extend into the late 2020s, with biosimilar competition expected thereafter.

3. Are there emerging markets for KADCYLA?
Yes, especially in Asia and Latin America, where HER2-positive breast cancer prevalence is high and access improves.

4. What clinical trials could impact KADCYLA's future?
Trials combining KADCYLA with immune checkpoint inhibitors or testing in other HER2-expressing cancers could expand its indication set.

5. How will healthcare policies in major markets influence revenue?
Stricter reimbursement criteria and pricing caps could restrict volume growth, while policy support for targeted therapies may enhance adoption.

---

References

[1] IQVIA, 2022. "Herceptin and KADCYLA Sales Data."
[2] FDA, 2020. "Approval Letter for KADCYLA in Early-Stage Breast Cancer."
[3] EvaluatePharma, 2023. "HER2-targeted ADC Market Analysis."